Evidence map›Paper›PMID 41324647›Full record

ReviewZeitschrift fur Rheumatologie2026

[Methotrexate osteopathy-a critical review].

Jürgen Braun, Björn Buehring

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jürgen BraunRheumatologisches Versorgungszentrum Steglitz, Schloßstr. 110, 12163, Berlin, Deutschland. j.braun@rvz-steglitz.de.
Björn BuehringRuhr Universität Bochum, Bochum, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antimetabolite methotrexate (MTX) was originally used in chemotherapeutic treatment for cancer. Since the early 1980s, MTX has become indispensable in the treatment of rheumatoid arthritis and is established worldwide as the standard of care for the treatment of many inflammatory rheumatic diseases. The mechanism of action of MTX is not completely understood; the adenosine signaling pathway likely plays a role. There are several undesired side-effects associated with MTX (e.g., nausea, elevated transaminase levels, and cytopenia). Based on numerous case reports, it is also postulated that there is MTX-induced osteopathy, which manifests as bone pain and insufficiency fractures. The present article presents the current data and evaluates it critically.

Indexed as

Arthritis, RheumatoidBone Diseases, MetabolicMethotrexateAntirheumatic AgentsEvidence-Based MedicineHumansAntirheumatic AgentsMethotrexateArthritisInsufficiency fracturesMethotrexate-induced osteopathyOsteoporosisStress fractures

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.